

Facts About RAPAFLO™ (silodosin)

Indication & Dosing	RAPAFLO™ (silodosin) is approved for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), or enlargement of the prostate. The recommended dosage is 8 mg once daily with a meal.
Mechanism of Action	RAPAFLO is an effective, selective alpha-1 adrenergic receptor antagonist. It binds with high affinity to the alpha (1A) receptors concentrated in the prostate, causing the smooth muscles in these tissues to relax and resulting in an improved urine flow and a reduction of BPH symptoms. The binding affinity for the alpha (1B) receptors that cause smooth muscle relaxation and blood pressure effects in the cardiovascular system is significantly lower, thereby maximizing target organ activity for treating BPH and minimizing the potential for side effects and interactions with other therapies.
Clinical Efficacy	<ul style="list-style-type: none">• The approval of RAPAFLO is based on two Phase 3 multi-center (88 sites), randomized, double-blind, placebo-controlled trials that evaluated a total of 923 patients with signs and symptoms of BPH• 8 mg, once-daily RAPAFLO for 12 weeks provided significant and rapid relief of BPH symptoms, compared with placebo, as measured by the International Prostate Symptom Score (IPSS)• RAPAFLO also demonstrated significant improvement on maximum urine flow after the first dose• Symptom relief was sustained through a 40-week open label trial
Safety	<ul style="list-style-type: none">• In clinical trials, RAPAFLO demonstrated strong and rapid efficacy with minimal effects on the cardiovascular system. The effect on blood pressure was similar between the RAPAFLO and placebo groups• Most drug-related adverse events were generally mild and resulted in low discontinuation• The most common adverse events were retrograde ejaculation (orgasm with reduced semen) and dizziness
Clinical Development	RAPAFLO was originally developed by Kissei Pharmaceutical Co., Ltd., in Japan and licensed to Watson for the United States, Canada and Mexico. Kissei successfully launched Urief® (silodosin) in Japan in May of 2006 at a twice daily dosing of 4mg. Urief® is marketed in cooperation with Daiichi Sankyo Pharmaceutical Co., Ltd.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

The mission of Watson Urology is to offer products and services that improve the quality of patients' lives, and satisfy the needs of physicians who specialize in the diagnosis, management, and treatment of urological disorders. By advancing education and support for urological diseases, we are creating the differences that make life more livable.

In the U.S., the Watson Urology portfolio includes: RAPAFLO™; Oxytrol®; TRELSTAR® LA; TRELSTAR® Depot; Androderm®; ProQuin® XR, under a co-promotion agreement with Depomed, Inc.; and AndroGel®, under a co-promotion agreement with Solvay Pharmaceuticals, Inc. The Watson portfolio also includes a number of products under development including: a six-month formulation of TRELSTAR® (triptorelin pamoate for injectable suspension), under development for the treatment of advanced prostate cancer; oxybutynin topical gel, under development for overactive bladder and Uracyst™, under development for cystitis.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at <http://www.watson.com>.

Forward-Looking Statement

Any statements contained in this document that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products, including RAPAFLO; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by the Company and the ability to successfully enforce such rights against third parties; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2007.